info:eu-repo/semantics/article
Vaccination with formulation of nanoparticles loaded with Leishmania amazonensis antigens confers protection against experimental visceral Leishmaniasis in hamster
Fecha
2023-01-02Registro en:
González, M.; Gonçalves, A.; Ottino, J.; Leite, J.; Resende, L.; Melo, O.; Silveira, P.; Cardoso, M.; Fujiwara, R.; Bueno, L.; Santos, R.; Carvalho, T.; Garcia, G.; Paes.; Galdino, A.; Chávez, M.; Melo, M.; Silveira, D.; Martins, O.; … Giunchetti, R. (2023). Vaccination with formulation of nanoparticles loaded with Leishmania amazonensis antigens confers protection against experimental visceral Leishmaniasis in hamster. Vaccines, 11(1), 111. doi: 10.3390/vaccines11010111
2076-393X
Autor
Maia Gonçalves, Ana Alice
Ottino, Jennifer
Costa Leite, Jaqueline
Aparecida Resende, Lucilene
Melo Júnior, Otoni Alves
Silveira, Patrícia
Santos Cardoso, Mariana
Toshio Fujiwara, Ricardo
Lacerda Bueno, Lilian
Lima Santos, Renato
Furtado de Carvalho, Tatiane
Martins Garcia, Giani
de Oliveira Paes, Paulo Ricardo
Sobreira Galdino, Alexsandro
Chávez Fumagalli, Miguel Angel
Martins Melo, Marília
Silveira Lemos, Denise
Martins Filho, Olindo Assis
Ornelas Dutra, Walderez
Furtado Mosqueira, Vanessa Carla
Cordeiro Giunchetti, Rodolfo
Institución
Resumen
Visceral leishmaniasis (VL) is a fatal disease caused by the protozoa Leishmania infantum for which dogs are the main reservoirs. A vaccine against canine visceral leishmaniasis (CVL) could be an important tool in the control of human and CVL by reducing the infection pressure of L. infantum. Despite the CVL vaccine available on the market, the Brazilian Ministry of Health did not implement the use of it in their control programs. In this sense, there is an urgent need to develop more efficient vaccines. In this study, the association between two polymeric nanoformulations, (poly (D, L-lactic) acid (PLA) polymer) loading Leishmania amazonensis antigens, was evaluated as a potential immunobiological agent against VL using golden hamsters as an experimental model. The results indicated that no significant adverse reactions were observed in animals vaccinated with LAPSmP. LAPSmP presented similar levels of total anti-Leishmania IgG as compared to LAPSmG. The LAPSmP and LAPSmG groups showed an intense reduction in liver and spleen parasitic load by qPCR. The LAPSmP and LAPSmG vaccines showed exceptional results, indicating that they may be promising candidates as a VL vaccine.